Tuberculosis in patients with systemic lupus erythematosus: a 37-year longitudinal survey-based study.

Background Infections are one of the most common causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). SLE patients have a higher risk of tuberculosis (TB) infection due to impaired immune defense. Objectives To investigate the demographics, clinical characteristics, and outcomes of patients with SLE and concomitant TB. Methods Medical records of SLE patients with TB who were admitted to Peking Union Medical College (PUMC) Hospital in 1983-2019 were retrospectively reviewed. Age-and sex-matched SLE inpatients without TB were randomly selected as controls. Clinical and laboratory features and treatment were analyzed and compared, and subjects were followed up to assess their outcome. Results Of the 10,469 SLE inpatients, 249 (2.4%) were diagnosed with TB. Compared with controls, SLE/TB+ patients exhibited higher frequency of prior hematologic, mucocutaneous, and musculoskeletal system involvement, and prior treatment with potent glucocorticoid/immunosuppressive agents (GC/ISA). Arthritis and alopecia, positive T-SPOT.TB test, and lymphocytopenia were more common in SLE/TB+ patients. SLE/TB+ patients with lupus before TB (SLE→TB) had higher risk of miliary TB (22.8%) and intracranial TB (16.5%) than SLE/TB+ patients with lupus after TB (TB→SLE). SLE/TB+ patients exhibited shorter long-term survival than SLE/TB- patients; those with poorer in-hospital outcomes had more severe lymphocytopenia and had received less treatment with ISAs. Conclusion SLE patients treated vigorously with GC/ISA should be alerted of increased risk of TB infection, especially miliary and intracranial TB. Positive T-SPOT.TB and lymphocytopenia served as discriminatory variables between SLE/TB+ and SLE/TB- patients. Lymphocytopenia was associated with poorer outcomes in SLE/TB+ patients.